Project Details
Description
With over 100,000 patients now on the waiting list for a kidney transplant, it is obvious that there is a critical
shortage of available donor organs. Xenotransplantation represents a promising solution. While pigs are
viewed as the optimal non-human source of organs, the potency of the human immune response to pig organs
has prevented the clinical application of pig-to-human kidney transplantation. In this application we propose
using cutting-edge genetic engineering approaches in combination with novel, clinically relevant immune-
suppressants to reduce both the humoral and cellular immune response of nonhuman primates undergoing
kidney xenotransplantation as a preclinical model to inform future human trials. With recent advances in
genome editing techniques we and others have created novel pig donors with multiple genetic alterations and
resultant improvements in xenograft survival. In addition, we have developed and applied strategies to avoid
early antibody mediated rejection by using a pre-transplant antibody screen similar to the crossmatch used in
clinical transplantation. We further identified CD4+ T cells as a critical subset in xenograft rejection and
demonstrated consistent long-term survival in the pig-to-primate kidney transplant model. These results
represent a major advance on the road to clinical translation of xenotransplantation. Here we propose to study
three major barriers to the clinical translation of xenotransplantation: (1) All long-term xenograft survival has
been dependent on antibody blockade of the CD40-CD154 pathway and there is currently no clinically
approved reagent. We will evaluate the only two clinically relevant CD40-CD154 pathway antagonists that are
in development and have shown efficacy in human patients: a) Iscalimab, a novel anti-CD40 antibody and b)
VIB4920, an innovative CD154-targeting protein. Neither of these new reagents has been tested in
xenotransplantation previously. (2) We will determine the impact of two novel desensitization treatments as
well as transient complement inhibition on early antibody mediated rejection. We will test imlifidase (IdeS, an
IgG degrading enzyme recently approved by the FDA for the prevention and treatment of antibody mediated
rejection) as well as an innovative desensitization strategy combining costimulation blockade and proteasome
inhibition. In addition to addressing early antibody mediated injury we will test a novel complement-directed
therapy, tesidolumab, an anti-C5 antibody that is currently being evaluated in clinical trials. We present
exciting data using the novel anti-C5 antibody tesidolumab, suggesting that targeted complement inhibition
mitigates early antibody rejection. (3) Lastly we will address the important issue of late antibody mediated
injury. Given our success we are uniquely positioned to study this important problem. Similar to clinical kidney
transplantation, we have new data that late kidney xenograft injury is directly related to the development of
anti-SLA class II antibody. We will test the importance of this finding by deleting the genes for SLA class II DQ
and DR in the porcine donor tissue and assessing the impact on rejection and protective immunity.
Status | Finished |
---|---|
Effective start/end date | 7/1/21 → 4/30/24 |
Funding
- National Institute of Allergy and Infectious Diseases: $1,456,529.00
- National Institute of Allergy and Infectious Diseases: $1,442,779.00
- National Institute of Allergy and Infectious Diseases: $1,442,779.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.